Takeda Pharmaceutical Company Limited (TAK)
Takeda Pharmaceutical Company Limited operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Tokyo, OS, JP. The stock last traded at $21.77, up 1.68% on the session, giving a market capitalisation of $69.55B. On trailing twelve-month figures it carries a trailing P/E of 28.48, a net margin of 8.2%. Its beta of 0.09 implies it has historically moved less than the broad market.
Takeda Pharmaceutical Company Limited is a global biopharmaceutical enterprise engaged in the discovery, development, manufacturing, marketing, and out-licensing of various medical products. The company's operations span Japan, the United States, Europe, Canada, Latin America, Russia, and other regions across Asia and internationally. Takeda concentrates its efforts on key therapeutic areas such as gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. Its extensive product range includes well-known brands like Entyvio, Takhzyro, Velcade, and Vyvanse. To advance its pipeline and innovation, Takeda actively fosters numerous collaborations, in-licensing agreements, research partnerships, and strategic alliances with a diverse array of organizations, including academic institutions like the University of Texas MD Anderson Cancer Center and biotech firms such as Neurocrine Biosciences, Inc. and Arrowhead Pharmaceuticals Inc. Established in 1781, the company maintains its headquarters in Tokyo, Japan.
Takeda Pharmaceutical Company Limited is most often compared with the following Healthcare names: